Vascular targeting in hepatocellular carcinoma with VEGFR-2 specific immunoliposomes containing doxorubicin

被引：0
|
作者：
Roth, P.
Hammer, C.
Piguet, A-C.
Dufour, J-F.
Waelti, E.
机构：
[1] Univ Bern, Div Immunopathol, Inst Pathol, CH-3012 Bern, Switzerland
[2] Univ Bern, Inst Clin Pharmacol, CH-3012 Bern, Switzerland
来源：
JOURNAL OF HEPATOLOGY | 2006年 / 44卷
关键词：
D O I：
10.1016/S0168-8278(06)80369-7
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
369
引用
收藏
页码：S141 / S141
页数：1
相关论文
共 50 条
  • [31] Use of VEGFR-2 Targeted Ultrasound Contrast Agent for the Early Evaluation of Response to Sorafenib in a Mouse Model of Hepatocellular Carcinoma
    Toaldo, Marco Baron
    Salvatore, Veronica
    Marinelli, Sara
    Palama, Chiara
    Milazzo, Maddalena
    Croci, Luca
    Venerandi, Laura
    Cipone, Mario
    Bolondi, Luigi
    Piscaglia, Fabio
    MOLECULAR IMAGING AND BIOLOGY, 2015, 17 (01) : 29 - 37
  • [32] Development and investigation of thiazolidinedione and pyrazoline compounds as antiangiogenic weapons targeting VEGFR-2
    Upadhyay, Neha
    Tilekar, Kalpana
    Safuan, Sabreena
    Kumar, Alan P.
    Schweipert, Markus
    Meyer-Almes, Franz-Josef
    Ramaa, C. S.
    FUTURE MEDICINAL CHEMISTRY, 2021, 13 (22) : 1963 - 1986
  • [33] Heterodimerization with vascular endothelial growth factor receptor-2 (VEGFR-2) is necessary for VEGFR-3 activity
    Alam, A
    Herault, JP
    Barron, P
    Favier, B
    Fons, P
    Delesque-Touchard, N
    Senegas, I
    Laboudie, P
    Bonnin, J
    Cassan, C
    Savi, P
    Ruggeri, B
    Carmeliet, P
    Bono, FO
    Herbert, JM
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2004, 324 (02) : 909 - 915
  • [34] VASCULAR ENDOTHELIAL GROWTH FACTOR A AND ITS RECEPTOR VEGFR-2 IN THE FELINE PLACENTA
    Gomez Castro, Gimena
    Barbeito, Claudio
    Merkis, Cecilia
    Casas, Luciano
    Diessler, Monica
    PLACENTA, 2022, 122 : E102 - E102
  • [35] VASCULAR ENDOTHELIAL GROWTH FACTOR AND HIS RECEPTORS, VEGFR-1 AND VEGFR-2, IN AIRWAYS OF PATIENTS WITH NSCLC
    Charpidou, Andriani G.
    Gkiozos, Ioannis
    Eleftheraki, Anastasia
    Gratsias, Manolis
    Fevranoglou, Christina
    Polyzos, Aris
    Syrigos, Kostas N.
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S945 - S946
  • [36] Emibetuzumab plus ramucirumab: Simultaneous targeting of MET and VEGFR-2 in patients with advanced hepatocellular cancer in a phase 1b/2 study
    Harding, James J.
    Bendell, Johanna C.
    Fuchs, Charles S.
    Wang, Xuejing
    Wacheck, Volker
    Zhu, Andrew X.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [37] Comparison of the prognosis indication of VEGFR-1 and VEGFR-2 and Tie2 receptor expression in breast carcinoma
    Meunier-Carpentier, S
    Dales, JP
    Djemli, A
    Garcia, S
    Bonnier, P
    Andrac-Meyer, L
    Lavaut, MN
    Allasia, C
    Charpin, C
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2005, 26 (04) : 977 - 984
  • [38] Novel VEGFR2 inhibitors with thiazoloquinoxaline scaffold targeting hepatocellular carcinoma with lower cardiotoxic impact
    El-Hazek, Reham M. M.
    Zaher, Nashwa H.
    El-Gazzar, Mostafa G. M.
    Fadel, Noha A.
    El-Sabbagh, Walaa A.
    SCIENTIFIC REPORTS, 2023, 13 (01):
  • [39] Novel VEGFR2 inhibitors with thiazoloquinoxaline scaffold targeting hepatocellular carcinoma with lower cardiotoxic impact
    Reham M. M. El-Hazek
    Nashwa H. Zaher
    Mostafa G. M. El-Gazzar
    Noha A. Fadel
    Walaa A. El-Sabbagh
    Scientific Reports, 13 (1)
  • [40] Enhanced Cancer Therapy with the Combination of EGFR and VEGFR-2 Targeting in an Orthotopic Glioblastoma Model
    Diao, Yi
    Tian, Xin-Hua
    Huang, Yan-Lin
    Chen, Lu-Kui
    Lin, Xiao-Ning
    Zhuang, Zai-Wang
    JOURNAL OF CHEMOTHERAPY, 2010, 22 (06) : 407 - 412
12345